N-(4-(pyridin-4-yl)phenyl)acetamide | 59656-60-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-(4-(pyridin-4-yl)phenyl)acetamide
• 英文别名: 4-(4-Acetamidophenyl)pyridine；N-(4-pyridin-4-ylphenyl)acetamide
• CAS: 59656-60-9
• 化学式: C₁₃H₁₂N₂O
• 分子量: 212.251
• InChiKey: FQMAHGGXAGIEQX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(4-(pyridin-4-yl)phenyl)acetamide 在 盐酸 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以89%的产率得到4-(吡啶-4-基)苯胺
  参考文献：
  名称：

  Synthesis and methemoglobinemia-inducing properties of benzocaine isosteres designed as humane rodenticides

  摘要：

  A number of isosteres (oxadiazoles, thiadiazoles, tetrazoles and diazines) of benzocaine were prepared and evaluated for their capacity to induce methemoglobinemia-with a view to their possible application as humane pest control agents. It was found that an optimal lipophilicity for the formation of methemoglobin (metHb) in vitro existed within each series, with 1,2,4-oxadiazole 3 (metHb% = 61.0 +/- 3.6) and 1,3,4-oxadiazole 10 (metHb% = 52.4 +/- 0.9) demonstrating the greatest activity. Of the 5 candidates (compounds 3, 10, 11, 13 and 23) evaluated in vivo, failure to induce a lethal end-point at doses of 120 mg/kg was observed in all cases. Inadequate metabolic stability, particularly towards hepatic enzymes such as the CYPs, was postulated as one reason for their failure. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.02.013
• 作为产物：
  描述：

  4-(吡啶-4-基)苯胺 生成 N-(4-(pyridin-4-yl)phenyl)acetamide
  参考文献：
  名称：

  Heilbron et al., Journal of the Chemical Society, 1940, p. 1279,1283

  摘要：

  DOI：

文献信息

• [EN] ARYL AMIDE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE L'ARYLAMIDE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015006100A1

  公开（公告）日：2015-01-15

  The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

  本公开涉及一般可抑制AAK1（适配器相关激酶1）的化合物，包括这些化合物的组合物，以及抑制AAK1的方法。
• Combination therapy with CHK1 inhibitors
  申请人：Gesner G. Thomas

  公开号：US20050256157A1

  公开（公告）日：2005-11-17

  Compounds of Structure I, and salts, tautomers, stereoisomers, and mixtures thereof may be used in methods of inhibiting checkpoint kinase 1 in subjects, in methods for inducing cell cycle progression, and in methods for increasing apoptosis in cells. Such compounds may be used to prepare pharmaceutical compositions and may be used in conjunction with DNA damaging agents.

  结构I的化合物及其盐类、互变异构体、立体异构体和混合物可用于抑制受试者中的检查点激酶1，用于诱导细胞周期进展的方法，以及用于增加细胞凋亡的方法。这些化合物可用于制备药物组合物，并且可以与DNA损伤剂联合使用。
• Inhibition of FGFR3 and treatment of multiple myeloma
  申请人：Cai Shaopei

  公开号：US20050261307A1

  公开（公告）日：2005-11-24

  Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma.

  提供了抑制成纤维母细胞生长因子受体3并治疗由纤维母细胞生长因子受体3介导的各种疾病的方法，包括向受试者施用结构I的化合物，其药学上可接受的盐，其互变异构体，或其互变异构体的药学上可接受的盐。具有结构I的化合物具有以下结构，其中具有本文描述的变量。这些化合物可用于制备用于抑制纤维母细胞生长因子受体3和用于治疗由纤维母细胞生长因子受体3介导的疾病，如多发性骨髓瘤的药物。
• Palladium‐Catalyzed Electrophilic Functionalization of Pyridine Derivatives through Phosphonium Salts
  作者：Yuan‐Yuan Che、Yanni Yue、Ling‐Zhi Lin、Bingbing Pei、Xuezu Deng、Chao Feng

  DOI：10.1002/anie.202006724

  日期：2020.9.14

  Herein, we report a highly efficient and practical method for pyridine‐derived heterobiaryl synthesis through palladium‐catalyzed electrophilic functionalization of easily available pyridine‐derived quaternary phosphonium salts. The nice generality of this reaction was goes beyond arylation, enabling facile incorporation of diverse carbon‐based fragments, including alkenyl, alkynyl, and also allyl

  本文中，我们报告了一种通过钯催化的易得的吡啶衍生的季phospho盐的亲电官能团合成吡啶衍生的杂二芳基化合物的高效实用方法。该反应的通用性超出了芳基化的范围，从而可以轻松地将各种碳基片段（包括烯基，炔基以及烯丙基片段）掺入吡啶核中。值得注意的是，银盐添加剂被发现对于成功实现这种转化至关重要，并且还描述了其作为金属转移介质的关键作用，该介质可确保吡啶基向钯中间体的平稳转移。
• <i>N</i>-Aryl-2-aminobenzimidazoles: Novel, Efficacious, Antimalarial Lead Compounds
  作者：Sreekanth Ramachandran、Shahul Hameed P.、Abhishek Srivastava、Gajanan Shanbhag、Sapna Morayya、Nikhil Rautela、Disha Awasthy、Stefan Kavanagh、Sowmya Bharath、Jitendar Reddy、Vijender Panduga、K. R. Prabhakar、Ramanatha Saralaya、Robert Nanduri、Anandkumar Raichurkar、Sreenivasaiah Menasinakai、Vijayashree Achar、María Belén Jiménez-Díaz、María Santos Martínez、Iñigo Angulo-Barturen、Santiago Ferrer、Laura María Sanz、Francisco Javier Gamo、Sandra Duffy、Vicky M. Avery、David Waterson、Marcus C. S. Lee、Olivia Coburn-Flynn、David A. Fidock、Pravin S. Iyer、Shridhar Narayanan、Vinayak Hosagrahara、Vasan K. Sambandamurthy

  DOI：10.1021/jm500715u

  日期：2014.8.14

  malaria. This compound displayed an excellent pharmacokinetic profile with a long half-life (19 h) in rat blood. This profile led to an extended survival of animals for over 30 days following a dose of 50 mg/kg in the Pb malaria model. Compound 12 retains its potency against a panel of Pf isolates with known mechanisms of resistance. The fast killing observed in the in vitro parasite reduction ratio (PRR)

  从阿斯利康公司化合物集合的表型筛选中，N-芳基-2-氨基苯并咪唑类化合物已成为对抗恶性疟原虫（Pf）无性血液阶段的新命中。药物化学对Pf和ADME性质的效力进行了优化，从而确定了12种为先导分子。化合物12在疟疾的伯氏疟原虫（Pb）模型中有效。该化合物在大鼠血液中显示出出色的药代动力学特征，具有长的半衰期（19小时）。在Pb剂量为50 mg / kg时，此特征导致动物延长了30天以上的生存期疟疾模型。化合物12保持其对具有已知抗性机制的Pf分离物组的效力。在体外寄生虫减少率（PRR）分析中观察到的快速杀灭作用与延长的生存期一起突显了这种新颖的化学类别用于治疗疟疾的希望。